FTC/Biovail Tiazac Settlement Blocks Royalties From Andrx On Generic
Executive Summary
The Federal Trade Commission consent order with Biovail regarding Tiazac voids a proposed settlement between the company and Andrx
You may also be interested in...
FTC Steps Into FDA’s ‘Ministerial’ Gap, Seeks Delisting Of REMS Patent
Jazz’s REMS patent appears to cover only a method of distributing Xyrem not a method of using the drug and if so should be delisted from FDA’s Orange Book, FTC argues in Jazz infringement suit against Avadel, which had itself sued FDA seeking release from patent certification requirement.
FTC Steps Into FDA’s ‘Ministerial’ Gap, Seeks Delisting Of REMS Patent
Jazz’s REMS patent appears to cover only a method of distributing Xyrem not a method of using the drug and if so should be delisted from FDA’s Orange Book, FTC argues in Jazz infringement suit against Avadel, which had itself sued FDA seeking release from patent certification requirement.
FTC Backs Single 30-Month Stay On Generic Rx Approvals In Patent Litigation
The Federal Trade Commission supports a limit of one 30-month stay of approval on generic drugs in patent litigation